Next Article in Journal
The Role of CT Imaging in Characterization of Small Renal Masses
Previous Article in Journal
Application of the AT(N) and Other CSF Classification Systems in Behavioral Variant Frontotemporal Dementia
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Serum S100B Levels in Patients with Liver Cirrhosis and Hepatic Encephalopathy

1
Ilsong Institute of Life Science, Hallym University, Seoul 07247, Republic of Korea
2
Department of Biomedical Gerontology, Graduate School of Hallym University, Chuncheon-si 24252, Republic of Korea
3
Department of Internal Medicine, Dongtan Sacred Heart Hospital of Hallym University Medical Center, 7, Keunjaebong-gil, Hwaseong-si 18450, Republic of Korea
4
Institute for Liver and Digestive Diseases, Hallym University, Chuncheon-si 24252, Republic of Korea
5
Department of Internal Medicine, Hallym University Sacred Heart Hospital of Hallym University Medical Center, 22, Gwanpyeong-ro 170 beon-gil, Dongan-gu, Anyang-si 14068, Republic of Korea
6
Department of Internal Medicine, Kangdong Sacred Heart Hospital of Hallym University Medical Center, 18, Cheonho-daero 173-gil, Gangdong-gu, Seoul 05355, Republic of Korea
7
Department of Internal Medicine, Kangnam Sacred Heart Hospital of Hallym University Medical Center, 1, Singil-ro, Yeongdeungpo-gu, Seoul 07441, Republic of Korea
8
Department of Internal Medicine, Chuncheon Sacred Heart Hospital of Hallym University Medical Center, 77, Sakju-ro, Chuncheon-si 24253, Republic of Korea
*
Author to whom correspondence should be addressed.
Diagnostics 2023, 13(3), 333; https://doi.org/10.3390/diagnostics13030333
Submission received: 5 December 2022 / Revised: 8 January 2023 / Accepted: 13 January 2023 / Published: 17 January 2023
(This article belongs to the Section Pathology and Molecular Diagnostics)

Abstract

Hepatic encephalopathy (HE) is one of the main complications of liver cirrhosis (LC) and is classified into minimal hepatic encephalopathy (MHE) and overt hepatic encephalopathy (overt HE). S100B is expressed mainly in astrocytes and other glial cells, and S100B has been reported to be associated with various neurological disorders. The present study aimed to investigate the diagnostic ability of serum S100B to discriminate the grade of HE and the parameters correlated with serum S100B levels. Additionally, we investigated whether serum S100B levels can be used to predict 1-year mortality in cirrhotic patients. In total, 95 cirrhotic patients were consecutively enrolled and divided into the following three groups: (i) without any types of HEs; (ii) with MHE; and (iii) with overt HE. The diagnosis of MHE was made by the Mini-Mental State Examination (MMSE) and Psychometric Hepatic Encephalopathy Score (PHES). Among the three groups, there were no significant differences in serum S100B levels regardless of HE severity. The clinical parameters correlated with serum S100B levels were age, serum bilirubin, and creatinine levels. The Model for End-Stage Liver Disease (MELD) score showed a significant positive correlation with serum S100B levels. The relationship between serum S100B levels and MELD score was maintained in 48 patients without any type of HE. Additionally, hyperammonemia, low cholesterol levels, and the combination of serum S100B levels ≥ 35 pg/mL with MELD score ≥ 13 were factors for predicting 1- year mortality. In conclusion, serum S100B level was not useful for differentiating the severity of HE. However, we found that serum S100B levels can be affected by age, serum bilirubin, and creatinine in cirrhotic patients and are associated with MELD scores. Additionally, serum S100B levels showed the possibility of predicting 1-year mortality in cirrhotic patients. These findings suggest that serum S100B levels may reflect liver dysfunction and prognosis in liver disease.
Keywords: S100B; hepatic encephalopathy; MELD; liver cirrhosis S100B; hepatic encephalopathy; MELD; liver cirrhosis

Share and Cite

MDPI and ACS Style

Kim, M.-J.; Kim, J.-H.; Jung, J.-H.; Kim, S.-E.; Kim, H.-S.; Jang, M.-K.; Park, S.-H.; Lee, M.-S.; Suk, K.T.; Kim, D.J.; et al. Serum S100B Levels in Patients with Liver Cirrhosis and Hepatic Encephalopathy. Diagnostics 2023, 13, 333. https://doi.org/10.3390/diagnostics13030333

AMA Style

Kim M-J, Kim J-H, Jung J-H, Kim S-E, Kim H-S, Jang M-K, Park S-H, Lee M-S, Suk KT, Kim DJ, et al. Serum S100B Levels in Patients with Liver Cirrhosis and Hepatic Encephalopathy. Diagnostics. 2023; 13(3):333. https://doi.org/10.3390/diagnostics13030333

Chicago/Turabian Style

Kim, Mo-Jong, Jung-Hee Kim, Jang-Han Jung, Sung-Eun Kim, Hyoung-Su Kim, Myoung-Kuk Jang, Sang-Hoon Park, Myung-Seok Lee, Ki Tae Suk, Dong Joon Kim, and et al. 2023. "Serum S100B Levels in Patients with Liver Cirrhosis and Hepatic Encephalopathy" Diagnostics 13, no. 3: 333. https://doi.org/10.3390/diagnostics13030333

APA Style

Kim, M.-J., Kim, J.-H., Jung, J.-H., Kim, S.-E., Kim, H.-S., Jang, M.-K., Park, S.-H., Lee, M.-S., Suk, K. T., Kim, D. J., Choi, E.-K., & Park, J.-W. (2023). Serum S100B Levels in Patients with Liver Cirrhosis and Hepatic Encephalopathy. Diagnostics, 13(3), 333. https://doi.org/10.3390/diagnostics13030333

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop